Phase II study of gemcitabine, bevacizumab and erlotinib in locally advanced and metastatic pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 26 Apr 2012 Actual patient number changed from 30 to 32 as reported by ClinicalTrials.gov.
- 19 Jul 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.